Canaccord Genuity cuts Ultragenyx Pharma PT to $37
Canaccord Genuity maintained a Buy rating on Ultragenyx Pharma while cutting its price target to $37.00 per share from $83.00.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.